Aignostics is an AI company developing precision medicine solutions that transform complex biomedical data into actionable insights for drug development and patient care. Aignostics began as a spin-off from Charité Berlin and operates with cross-functional teams in Berlin and New York. The company's mission is to improve patient outcomes through AI-driven discovery and translational tools.

Aignostics builds pathology foundation models and delivers the Atlas H&E-TME product for comprehensive tumor microenvironment profiling. The company also provides custom services across the drug development lifecycle, including target and biomarker discovery, translational research, and digital diagnostics for clinical validation and regulated use.

Aignostics has proprietary access to multimodal pathology data from over 30 million patients across partner hospitals and laboratories. Their team includes data scientists, machine learning engineers, pathologists and biologists. The company is ISO 13485 and ISO 27001 certified and offers a GCP-ready clinical trial platform, with active collaborations with leading academic partners.